WO1999055843A3 - Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects - Google Patents

Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects Download PDF

Info

Publication number
WO1999055843A3
WO1999055843A3 PCT/CA1999/000369 CA9900369W WO9955843A3 WO 1999055843 A3 WO1999055843 A3 WO 1999055843A3 CA 9900369 W CA9900369 W CA 9900369W WO 9955843 A3 WO9955843 A3 WO 9955843A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
cells
methods
efficient
hiv infected
Prior art date
Application number
PCT/CA1999/000369
Other languages
French (fr)
Other versions
WO1999055843A2 (en
Inventor
David Bell
Kenneth Rosenthal
Original Assignee
Hemosol Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemosol Inc filed Critical Hemosol Inc
Priority to CA002326378A priority Critical patent/CA2326378A1/en
Priority to NZ508242A priority patent/NZ508242A/en
Priority to EP99917710A priority patent/EP1073720A2/en
Priority to AU35911/99A priority patent/AU769538B2/en
Publication of WO1999055843A2 publication Critical patent/WO1999055843A2/en
Publication of WO1999055843A3 publication Critical patent/WO1999055843A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0081—Purging biological preparations of unwanted cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Methods for the expansion of CD4, CD8, and DP T-cells from HIV infected patients are disclosed which allow the maintenance of low levels of HIV. The invention further discloses methods for the inhibition of HIV gene expression. Also disclosed are methods for the rapid and efficient screening of cells derived from HIV-infected patients to assess the suitability of various antiviral treatments. The invention further provides a means for the generation of cell banks for use in immune reconstitution and means of treating or modifying expanded cell populations prior to infusion to enhance or modulate therapeutic effectiveness.
PCT/CA1999/000369 1998-04-24 1999-04-23 Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects WO1999055843A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002326378A CA2326378A1 (en) 1998-04-24 1999-04-23 Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects
NZ508242A NZ508242A (en) 1998-04-24 1999-04-23 Efficient ex vivo expansion of CD4+ and CD8+ T-Cells from HIV infected subjects
EP99917710A EP1073720A2 (en) 1998-04-24 1999-04-23 Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects
AU35911/99A AU769538B2 (en) 1998-04-24 1999-04-23 Efficient ex vivo expansion of CD4+ and CD8+ T-cells from HIV infected subjects

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8286198P 1998-04-24 1998-04-24
US60/082,861 1998-04-24

Publications (2)

Publication Number Publication Date
WO1999055843A2 WO1999055843A2 (en) 1999-11-04
WO1999055843A3 true WO1999055843A3 (en) 2000-01-13

Family

ID=22173909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000369 WO1999055843A2 (en) 1998-04-24 1999-04-23 Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects

Country Status (7)

Country Link
US (1) US6610542B1 (en)
EP (1) EP1073720A2 (en)
AU (1) AU769538B2 (en)
CA (1) CA2326378A1 (en)
NZ (1) NZ508242A (en)
WO (1) WO1999055843A2 (en)
ZA (1) ZA200006837B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8412377B2 (en) 2000-01-24 2013-04-02 Irobot Corporation Obstacle following sensor scheme for a mobile robot
WO2004003142A2 (en) * 2002-06-28 2004-01-08 Xcyte Therapies, Inc. Compositions and methods for restoring immune repertoire in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040175373A1 (en) * 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
JP4111394B2 (en) * 2003-12-22 2008-07-02 北海道ティー・エル・オー株式会社 Method for producing modified targeted T cell and pharmaceutical
BRPI0611766A2 (en) 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc methods and compositions for the treatment of persistent infections and cancer by inhibition of the programmed cell death pathway
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc Heteroduplex tracking assay
HUE030139T2 (en) * 2006-12-27 2017-04-28 Univ Emory Compositions and methods for the treatment of infections
AU2009319701B2 (en) * 2008-11-28 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods for the treatment of infections and tumors
WO2014134547A1 (en) * 2013-02-28 2014-09-04 Therabiol, Inc. Hiv antigens and antibodies
US20170360920A1 (en) * 2014-11-20 2017-12-21 The Johns Hopkins University Method and compositions for the prevention and treatment of a hiv infection

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016715A1 (en) * 1993-01-27 1994-08-04 Hemosol, Inc. Selective cell proliferation
WO1997005239A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1998033891A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2263978A1 (en) 1996-08-27 1998-03-05 Hemosol Inc. Enhanced stimulation of erythropoiesis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994016715A1 (en) * 1993-01-27 1994-08-04 Hemosol, Inc. Selective cell proliferation
WO1997005239A1 (en) * 1995-07-25 1997-02-13 Celltherapy, Inc. Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
WO1998033891A1 (en) * 1997-01-31 1998-08-06 Hemosol Inc. Method for the production of selected lymphocytes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
COCCHI F ET AL: "IDENTIFICATION OF RANTES, MIP-1ALPHA, AND MIP-1BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8+ T CELLS", SCIENCE, vol. 270, 15 December 1995 (1995-12-15), pages 1811 - 1815, XP000616644, ISSN: 0036-8075 *
HO M ET AL: "A phase 1 study of adoptive transfer of autologous CD8 + T lymphocytes in patients with acquired immunodeficiency syndrome (AIDS)-related complex or AIDS.", BLOOD, (1993 APR 15) 81 (8) 2093-101., XP002121508 *
KAY NE ET AL: "Expansion of a lymphocyte population co-expressing T4 (CD4) and T8 (CD8) antigens in the peripheral blood of a normal adult male", BLOOD, vol. 75, no. 10, 15 May 1990 (1990-05-15), pages 2024 - 9, XP002121509 *
LHOTAK ET AL: "Efficient ex vivo expansion of T cells from HIV-infected individuals using XLCMTM", BLOOD, vol. 92, no. 10, 15 November 1998 (1998-11-15), pages 168A, XP002105037, ISSN: 0006-4971 *
POZNANSKY M C ET AL: "Inhibition of human immunodeficiency virus replication and growth advantage of CD4 + T cells from HIV -infected individuals that express intracellular antibodies against HIV -1 gp120 or Tat.", HUMAN GENE THERAPY, (1998 MAR 1) 9 (4) 487-96., XP002121507 *
SKEA ET AL: "Large ex vivo expansion and reduced alloreactivity of umbilical cord blood T lymphocytes", BLOOD, vol. 90, no. 10, 15 November 1997 (1997-11-15), pages 368A, XP002105221, ISSN: 0006-4971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date
WO1999055843A2 (en) 1999-11-04
NZ508242A (en) 2003-05-30
AU3591199A (en) 1999-11-16
EP1073720A2 (en) 2001-02-07
CA2326378A1 (en) 1999-11-04
ZA200006837B (en) 2001-05-22
AU769538B2 (en) 2004-01-29
US6610542B1 (en) 2003-08-26

Similar Documents

Publication Publication Date Title
WO1999055843A3 (en) Efficient ex vivo expansion of cd4+ and cd8+ t-cells from hiv infected subjects
PT1137436E (en) Stimulation of t-cells against self antigens using ctla-4 blocking agents
WO1991003248A3 (en) Method for immune system activation
WO2002008389A3 (en) Therapeutic angiogenesis by bone marrow-derived cell transplantation in myocardial ischemic tissue and skeletal muscle ischemic tissue
WO2001036589A3 (en) Human ex vivo immune system
AU8476698A (en) Human mesenchymal stem cells from peripheral blood
WO2001069283A3 (en) Method and apparatus for dynamic focusing of ultrasound energy
EP0832203A4 (en) Use of neuro-derived fetal cell lines for transplantation therapy
DK1634949T3 (en) Method of generating activated T cells and antigen-incubated antigen-presenting cells
DK1412485T3 (en) Antigen presenting cells, method of treatment and use thereof for cancer vaccines
BG103714A (en) Pararacetamol-containing tablet
WO2001026704A3 (en) Targeted drug activation
ATE157370T1 (en) OLIGONUCLEOTIDES ACTIVE AGAINST THE RESPIRATORY SYNZYTIAL VIRUS
AU2002303437A1 (en) Isolation of neural stem cells using gangliosides and other surface markers
WO1999032634A3 (en) Compositions derived from mycobacterium vaccae and methods for their use
WO1999012951A8 (en) Uses of nicotinamide adenine dinucleotide and its analogs for treatment of malignant and infectious diseases
WO1999046371A3 (en) Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
HUP9901858A2 (en) Method for inhibiting adenylosuccinate synthetase activity methylthioadenosine phosphorylase deficient cells
IE893991L (en) 2',3'-dideoxypurine nucleoside/purine nucleoside¹phosphorylase inhibitor combination therapy and composition
DE60016429D1 (en) CELL AND / OR TUMOR-SPECIFIC PROMOTER-DEPENDENT CHANGE OF THE TARGETED EXPRESSION OF HERPES GAMMA 34.5 GENE
WO2003045335A3 (en) Stem cell screening and transplantation therapy for hiv infection
HK1047294A1 (en) Surface for cell culture
CA2347178A1 (en) Methods of inhibiting smooth muscle cell proliferation and preventing restenosis with a vector expressing rb2/p130
MX9803610A (en) Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Kind code of ref document: A

Ref document number: 2326378

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 508242

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2000/06837

Country of ref document: ZA

Ref document number: 200006837

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 35911/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999917710

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999917710

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999917710

Country of ref document: EP